S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:PCVX

Vaxcyte Competitors

$23.62
-2.21 (-8.56 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.42
Now: $23.62
$26.19
50-Day Range
$23.56
MA: $25.29
$27.90
52-Week Range
$17.80
Now: $23.62
$58.47
Volume397,419 shs
Average Volume362,415 shs
Market Capitalization$1.20 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Vaxcyte (NASDAQ:PCVX) Vs. IOVA, CBPO, ALLO, BEAM, RLAY, and SWTX

Should you be buying PCVX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Vaxcyte, including Iovance Biotherapeutics (IOVA), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Beam Therapeutics (BEAM), Relay Therapeutics (RLAY), and SpringWorks Therapeutics (SWTX).

Iovance Biotherapeutics (NASDAQ:IOVA) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Profitability

This table compares Iovance Biotherapeutics and Vaxcyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Iovance BiotherapeuticsN/A-50.64%-45.64%
VaxcyteN/AN/AN/A

Institutional & Insider Ownership

94.6% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 74.1% of Vaxcyte shares are owned by institutional investors. 9.9% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Iovance Biotherapeutics and Vaxcyte's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-19.98
VaxcyteN/AN/A$-50,270,000.00N/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Iovance Biotherapeutics and Vaxcyte, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Iovance Biotherapeutics02802.80
Vaxcyte00403.00

Iovance Biotherapeutics presently has a consensus target price of $50.10, indicating a potential upside of 57.70%. Vaxcyte has a consensus target price of $48.00, indicating a potential upside of 103.22%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Iovance Biotherapeutics.

Summary

Vaxcyte beats Iovance Biotherapeutics on 5 of the 8 factors compared between the two stocks.

Vaxcyte (NASDAQ:PCVX) and China Biologic Products (NASDAQ:CBPO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Vaxcyte and China Biologic Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaxcyteN/AN/AN/A
China Biologic Products27.43%8.32%7.64%

Insider and Institutional Ownership

74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 34.8% of China Biologic Products shares are owned by institutional investors. 2.7% of China Biologic Products shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Vaxcyte and China Biologic Products' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A$-50,270,000.00N/AN/A
China Biologic Products$503.70 million9.23$138.81 million$4.2827.58

China Biologic Products has higher revenue and earnings than Vaxcyte.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxcyte and China Biologic Products, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxcyte00403.00
China Biologic Products0000N/A

Vaxcyte presently has a consensus price target of $48.00, indicating a potential upside of 103.22%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than China Biologic Products.

Summary

China Biologic Products beats Vaxcyte on 6 of the 9 factors compared between the two stocks.

Vaxcyte (NASDAQ:PCVX) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Vaxcyte and Allogene Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaxcyteN/AN/AN/A
Allogene TherapeuticsN/A-27.59%-24.97%

Insider and Institutional Ownership

74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are owned by institutional investors. 31.3% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Vaxcyte and Allogene Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A$-50,270,000.00N/AN/A
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-17.72

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxcyte and Allogene Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxcyte00403.00
Allogene Therapeutics031302.81

Vaxcyte presently has a consensus price target of $48.00, indicating a potential upside of 103.22%. Allogene Therapeutics has a consensus price target of $52.0833, indicating a potential upside of 60.60%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Allogene Therapeutics.

Summary

Vaxcyte beats Allogene Therapeutics on 6 of the 8 factors compared between the two stocks.

Vaxcyte (NASDAQ:PCVX) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Vaxcyte and Beam Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaxcyteN/AN/AN/A
Beam Therapeutics-529,075.00%-103.41%-48.05%

Insider and Institutional Ownership

74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are owned by institutional investors. 0.7% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Vaxcyte and Beam Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A$-50,270,000.00N/AN/A
Beam Therapeutics$20,000.00212,996.07$-78,330,000.00($14.05)-5.23

Vaxcyte has higher earnings, but lower revenue than Beam Therapeutics.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxcyte and Beam Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxcyte00403.00
Beam Therapeutics03302.50

Vaxcyte presently has a consensus price target of $48.00, indicating a potential upside of 103.22%. Beam Therapeutics has a consensus price target of $96.00, indicating a potential upside of 30.63%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Beam Therapeutics.

Summary

Vaxcyte beats Beam Therapeutics on 8 of the 10 factors compared between the two stocks.

Vaxcyte (NASDAQ:PCVX) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Vaxcyte and Relay Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaxcyteN/AN/AN/A
Relay TherapeuticsN/AN/AN/A

Insider and Institutional Ownership

74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Vaxcyte and Relay Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A$-50,270,000.00N/AN/A
Relay TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxcyte and Relay Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxcyte00403.00
Relay Therapeutics01502.83

Vaxcyte presently has a consensus price target of $48.00, indicating a potential upside of 103.22%. Relay Therapeutics has a consensus price target of $57.40, indicating a potential upside of 43.54%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Relay Therapeutics.

Vaxcyte (NASDAQ:PCVX) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Vaxcyte and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaxcyteN/AN/AN/A
SpringWorks TherapeuticsN/A-24.48%-23.58%

Insider and Institutional Ownership

74.1% of Vaxcyte shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Vaxcyte and SpringWorks Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A$-50,270,000.00N/AN/A
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-19.52

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxcyte and SpringWorks Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxcyte00403.00
SpringWorks Therapeutics00303.00

Vaxcyte presently has a consensus price target of $48.00, indicating a potential upside of 103.22%. SpringWorks Therapeutics has a consensus price target of $91.00, indicating a potential upside of 31.31%. Given Vaxcyte's higher probable upside, analysts plainly believe Vaxcyte is more favorable than SpringWorks Therapeutics.

Summary

Vaxcyte beats SpringWorks Therapeutics on 5 of the 7 factors compared between the two stocks.


Vaxcyte Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$31.77-7.6%$4.67 billionN/A-16.55Analyst Upgrade
High Trading Volume
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.06-0.1%$4.65 billion$503.70 million32.98Upcoming Earnings
Increase in Short Interest
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.43-2.0%$4.56 billionN/A-15.23
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$73.49-14.0%$4.26 billion$20,000.00-5.23
RLAY
Relay Therapeutics
1.8$39.99-3.5%$3.60 billionN/A0.00
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$69.30-7.8%$3.39 billionN/A-39.83Analyst Report
Revolution Medicines logo
RVMD
Revolution Medicines
1.6$42.45-1.7%$2.82 billion$50.04 million0.00Earnings Announcement
Analyst Report
NantKwest logo
NK
NantKwest
1.1$25.75-3.2%$2.81 billion$40,000.00-36.27Decrease in Short Interest
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.4$40.36-6.9%$2.72 billion$20.53 million-23.20Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$61.01-12.9%$2.69 billion$125.57 million-35.68Earnings Announcement
Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81-3.0%$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53-7.5%$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.